New hope for kids with Tough-to-Treat cancer: trial tests powerful drug combo
NCT ID NCT07013565
Summary
This study is testing a new treatment approach for children, teens, and young adults whose ALK-positive anaplastic large cell lymphoma has come back or hasn't responded to prior therapy. The treatment combines an immunotherapy drug (nivolumab) with chemotherapy, followed by a stem cell transplant from a donor. Researchers hope this intensive, multi-step approach will help control the cancer and improve survival rates for this high-risk group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New York Medical College
Valhalla, New York, 10595, United States
Conditions
Explore the condition pages connected to this study.